RPS7

Across TCGA pan-cancer cohorts, RPS7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS7 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPS7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPS7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where RPS7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.418	0.716	<.001	22	view →
LUAD	DFS	Median	All	0.984	0.816	.001	9	view →
CCRCC	OS	Tertile	All	0.757	0.917	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPS7–PDAC (OS)

Open the PDAC breakdown →